Traceable nanoparticles with mitochondria-targeting pyruvate-Cu induce cuproptosis for enhanced triple-negative breast cancer therapy in a mouse model

Abstract

We develop pyruvate with good biocompatibility and mitochondria-targeting ability as a copper ionophore (pyruvate-Cu). To further address its drawbacks, traceable nanoparticles are constructed to deliver pyruvate-Cu for triple negative breast cancer (TNBC) treatment. In vitro and in vivo results demonstrate that this work provides an efficient platform for enhanced TNBC therapy.

Graphical abstract: Traceable nanoparticles with mitochondria-targeting pyruvate-Cu induce cuproptosis for enhanced triple-negative breast cancer therapy in a mouse model

Supplementary files

Article information

Article type
Communication
Submitted
04 Jun 2025
Accepted
18 Aug 2025
First published
20 Aug 2025

Mater. Horiz., 2025, Advance Article

Traceable nanoparticles with mitochondria-targeting pyruvate-Cu induce cuproptosis for enhanced triple-negative breast cancer therapy in a mouse model

C. Peng, J. Li, N. Wang, X. Zhang, W. Zhang, Z. Li, K. Zhang, Y. Ji, W. He and Y. Li, Mater. Horiz., 2025, Advance Article , DOI: 10.1039/D5MH01047K

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements